Trials / Recruiting
RecruitingNCT05527418
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Eva Bonfill · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | Dasatinib monotherapy 70 mg/day, during 16 weeks. |
| DRUG | Placebo | Placebo during 16 weeks. |
Timeline
- Start date
- 2024-01-26
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2022-09-02
- Last updated
- 2025-05-01
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05527418. Inclusion in this directory is not an endorsement.